As Dai­ichi Sankyo-part­nered breast can­cer drug march­es to­ward fin­ish line, As­traZeneca brings in Cana­di­an sci­en­tist Sunil Ver­ma to rev up R&D

Months af­ter As­traZeneca chief Pas­cal So­ri­ot forced out Med­Im­mune’s head of clin­i­cal on­col­o­gy de­vel­op­ment Mo­hammed Dar in a sweep­ing re­struc­tur­ing, the British drug­mak­er is ush­er­ing in Sunil Ver­ma as head of breast can­cer strat­e­gy as part of its on­col­o­gy R&D wing, as it sharp­ens its fo­cus on its keen­ly an­tic­i­pat­ed Dai­ichi Sankyo-part­nered an­ti­body-drug con­ju­gate.

Buoyed by the per­for­mance of As­traZeneca’s on­col­o­gy drugs, in March So­ri­ot bet big to part­ner with Dai­ichi Sankyo on its ex­per­i­men­tal breast can­cer drug, with $1.35 bil­lion up­front in a deal worth up to rough­ly $7 bil­lion. Last week, the Japan­ese drug­mak­er said the ther­a­py had cleared a piv­otal mid-stage study, paving the way for reg­u­la­to­ry sub­mis­sions in the first half of fis­cal 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER